Adamis Pharmaceuticals

185 articles about Adamis Pharmaceuticals

• Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business Update

  11/5/2020

  Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, November 9, 2020 at 2:00 pm Pacific Time to discuss its financial and operating results for the third quarter of 2020 as well as provide an update on business developments and activities.  The company’s press release concerning its third quarter 2020 financial results will be available after 1:00 p.m. Pacific Time

• Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Sep 18, 2020

  9/18/2020

  Adamis Pharmaceuticals Corporation announced the pricing of its previously announced underwritten public offering of 16,129,032 shares of its common stock at a public offering price of $0.62 per share, resulting in gross proceeds of approximately $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the company.

• Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock - Sep 17, 2020

  9/17/2020

  Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.

• Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders - Sep 03, 2020

  9/3/2020

  Adamis Pharmaceuticals Corporatio announced the results of its reconvened 2020 annual meeting of stockholders which was initially held August 20, 2020, and was adjourned until September 3, 2020

• Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders and Proposals

  8/25/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided additional information concerning the proposals to be considered at its adjourned 2020 annual meeting of stockholders, which will resume on September 3, 2020 at 10:00 a.m. Pacific Time. 

• Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders

  8/21/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2020 Annual Meeting of Stockholders (“Annual Meeting”), convened on Thursday, August 20, 2020, has been adjourned and will resume on September 3, 2020 at 10:00 a.m. Pacific Time, to permit additional time for solicitation of proxies with respect to two of the proposals described in the company’s notice of meeting and definitive proxy statement filed with the Securities and

• Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update

  8/17/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2020 and provided a business update.

• Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19

  8/14/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that in response to Adamis’ Pre-Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA), the FDA has provided detailed comments regarding the prospective use of Tempol in a randomized placebo controlled trial.

• Adamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

  8/5/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has received a letter from the NASDAQ Listing Qualifications Staff (“Nasdaq”) notifying the company that as a result of the closing bid price of the company’s common stock having been at $1.00 per share or greater for at least ten consecutive business days,

• Adamis Pharmaceuticals Provides Update on SYMJEPI Products

  7/1/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC (“USWM” or “US WorldMeds”) began promoting Adamis’ SYMJEPI ® (epinephrine) Injection 0.3mg and SYMJEPI ® (epinephrine) Injection 0.15mg products through its field sales force. As contemplated by the previously announced termination agreement between Adamis and Sandoz Inc., and the previously announced exclusive distribution and commercializatio

• Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose

  6/18/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the publication of an article entitled “Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level” in the peer reviewed publication “PLOS ONE, ” This study was done in collaboration with Rosa and Co.

• Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19

  6/15/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today a license  to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19).  The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.  In addition, the exclusive license includes the use of Tempol for reducing radiation

• Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone

  5/27/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the publication of an article entitled “An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability study comparing 5 mg/0.5 ml of intramuscular naloxone hydrochloride to 2 mg/0.4 ml intramuscular naloxone hydrochloride autoinjector in healthy subjects“ in the peer reviewed publication “ The Journal of Opioid Management .” The article co

• Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA

  5/18/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the resubmission of the Company’s New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for its ZIMHI ™ (naloxone HCI Injection, USP) 5mg/0.5mL product candidate for the treatment of opioid overdose. The resubmission follows the company’s meeting with the agency in February and is intended to address the issues raised by the FDA in the agency’s November 201

• Adamis Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update

  5/18/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2020 and provided a business update.

• Adamis Pharmaceuticals Schedules First Quarter 2020 Earnings Conference Call and Business Update

  5/15/2020

  Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, May 18, 2020 at 2:00 pm Pacific Time to discuss its financial and operating results for the first quarter of 2020 as well as provide an update on business developments and activities. The company’s press release concerning its first quarter 2020 financial results will be available after 1:00 p.m. Pacific Time on Ma

• Adamis Pharmaceuticals Provides Update on SYMJEPI Products and Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI Products

  5/11/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced it is reacquiring from Sandoz Inc. the rights to its SYMJEPI ® (epinephrine) Injection 0.3mg, SYMJEPI® (epinephrine) Injection 0.15mg products currently marketed and available in the United States.

• Adamis Pharmaceuticals Announces Publication Demonstrating PET Scan Results of Higher Dose Naloxone in Monkeys

  4/23/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced publication in the peer reviewed journal Molecules, “The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys” ( https://www.mdpi.com/1420-3049/25/6/1360 ).  Naloxone is an opioid antagonist that binds the opioid receptors in the brain (mu receptors) and displaces opioid-bound drugs thereby reversing toxicity and resuscitating

• Adamis Pharmaceuticals Announces Production of Additional Drugs by its US Compounding Subsidiary to Aid in the COVID-19 Pandemic

  4/21/2020

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), has increased its product mix to provide additional drugs to assist in the ongoing fight against COVID-19.

• Adamis Pharmaceuticals Announces Receipt of Loan Proceeds Under Paycheck Protection Program

  4/15/2020

  Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that it has received loan proceeds of $3,191,700 (“PPP Loan”) under the Paycheck Protection Program (“PPP”).  The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly payroll expenses of the qualifying business, calculated as provided under the P